Drug Trial Radar · NCT06820723
A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Nov 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Ohio State UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.
Conditions
- Depression
- Anxiety
- Major Depressive Disorder
Interventions
CYB003Drug
synthetic, deuterated isotopomer of psilocin
PlaceboDrug
Placebo orange drink solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in parameter estimate of regional brain activity measured by fMRI after one dose of CYB003 in participants with MDD and anxietyTime frame: Between Baseline and Time point 24 hours and 21 days post-Investigational Product or placebo
- Changes in region-to-region connectivity measured by fMRI after one dose of CYB003 in patients with depression and anxietyTime frame: Between Baseline and Time point 24 hours and 21 days post-Investigational Product or placebo
- Changes in event related potentials (ERP) after one dose of CYB003 in participants with MDD and anxietyTime frame: Between Baseline and Time point 24 hours and 21 days post-Investigational Product or placebo.
- Changes in acoustic startle electromyographic (EMG) response after one dose of CYB003 in patients with depression and anxietyTime frame: Between Baseline and Time point 24 hours and 21 days post-Investigational Product or placebo.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Ohio State University Department of Psychiatry
Columbus, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.